<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2012//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_120101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">11026535</PMID>
        <DateCreated>
            <Year>2001</Year>
            <Month>01</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2001</Year>
            <Month>03</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2007</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0968-0896</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>8</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2000</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Bioorganic &amp; medicinal chemistry</Title>
                <ISOAbbreviation>Bioorg. Med. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2219-27</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The three-dimensional structure of the complex between an HIV-1 cell-entry inhibitor selected from screening a combinatorial library of non-natural building blocks and the central, trimeric, coiled-coil core of HIV-1 gp41 has been determined by X-ray crystallography. The biased combinatorial library was designed to identify ligands binding in nonpolar pockets on the surface of the coiled-coil core of gp41. The crystal structure shows that the non-peptide moiety of the inhibitor binds to the targeted cavity in two different binding modes. This result suggests a strategy for increasing inhibitor potency by use of a second-generation combinatorial library designed to give simultaneous occupancy of both binding sites.</AbstractText>
            </Abstract>
            <Affiliation>Laboratory of Molecular Medicine, The Children's Hospital, Boston, MA 02115, USA.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferrer</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chopra</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kapoor</LastName>
                    <ForeName>T M</ForeName>
                    <Initials>TM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Strassmaier</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weissenhorn</LastName>
                    <ForeName>W</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Skehel</LastName>
                    <ForeName>J J</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oprian</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schreiber</LastName>
                    <ForeName>S L</ForeName>
                    <Initials>SL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harrison</LastName>
                    <ForeName>S C</ForeName>
                    <Initials>SC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wiley</LastName>
                    <ForeName>D C</ForeName>
                    <Initials>DC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>GM-39589</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType>Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Bioorg Med Chem</MedlineTA>
            <NlmUniqueID>9413298</NlmUniqueID>
            <ISSNLinking>0968-0896</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Anti-HIV Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>HIV Envelope Protein gp41</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Ligands</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Peptides</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anti-HIV Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Binding Sites</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Combinatorial Chemistry Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Crystallography, X-Ray</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">HIV Envelope Protein gp41</DescriptorName>
                <QualifierName MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">HIV-1</DescriptorName>
                <QualifierName MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Ligands</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Models, Molecular</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Molecular Conformation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Molecular Mimicry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Peptides</DescriptorName>
                <QualifierName MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Protein Binding</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2000</Year>
                <Month>10</Month>
                <Day>12</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2001</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2000</Year>
                <Month>10</Month>
                <Day>12</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11026535</ArticleId>
            <ArticleId IdType="pii">S0968-0896(00)00155-3</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
